Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition (NASDAQ: ACOG) enrolled the first patient in BEACON, a Phase 4 real-world effectiveness study evaluating ZUNVEYL in long-term care (LTC) residents with Alzheimer’s disease.
BEACON is a post-approval study planned for ~200 patients across multiple sites, collecting cognition, neuropsychiatric, safety, and tolerability data; topline results are expected in Q4 2026.
Alpha Cognition (NASDAQ: ACOG) announced the USPTO has issued U.S. Patent No. 12,551,491 covering dosage regimens for benzgalantamine, which the company says supports oral dosing methods for treating mild to moderate Alzheimer’s disease. The patent is expected to protect ZUNVEYL in the U.S. through July 2045.
Alpha Cognition said the method-of-use claims reinforce its patent portfolio, bolster ZUNVEYL’s long-term differentiation, and advance the company’s intellectual property strategy for benzgalantamine administration.
Alpha Cognition (NASDAQ: ACOG) outlined 2026 priorities to scale commercialization of ZUNVEYL, targeting ~2,000 prescribing healthcare providers and deeper nursing home penetration. The company expects payor coverage expansion via additional PBM contracts in 2026, plans three ZUNVEYL studies (CONVERGE ~400-patient retrospective, BEACON real-world effectiveness, RESOLVE phase 4), and anticipates multiple ex-US country approvals and a conditional $3 million licensing milestone in Q1. 2025 milestones included a $44 million exclusive Asia licensing deal, China NDA acceptance for CMS, a $40 million capital raise, patent protection through 2044, and ~600 HCPs with >500 nursing homes prescribing by Q3 2025.
Alpha Cognition (Nasdaq: ACOG) will participate in a virtual fireside chat hosted by Titan Partners to discuss commercialization efforts and research initiatives aimed at accelerating commercial adoption.
Event details: Titan Partners Fireside Chat on December 2, 2025, 12:00 pm–1:00 pm ET; participant Michael McFadden, CEO; host Boris Peaker, Managing Director, Titan Partners. Registration is available via the provided webinar link.
Alpha Cognition (NASDAQ: ACOG) reported accelerating 3Q25 commercialization of ZUNVEYL, driven by expansion in the U.S. long-term care channel. Pharmacy orders grew 102% sequentially, prescription volumes hit record monthly highs, and reach extended to >600 nursing homes with a prescriber base above 500 clinicians. Revenue for the quarter was $2.8M, comprising $2.3M of ZUNVEYL net product sales and $0.5M of licensing revenue. Pro forma cash after an October equity raise is about $73.2M, with a $75M ATM facility and roughly two years of runway at planned operating spend. Management continues to prioritize an LTC-focused call strategy to drive durable adoption and repeat ordering.
Alpha Cognition (Nasdaq: ACOG) reported Q3 2025 results and operational progress for ZUNVEYL on November 13, 2025. The company recorded $2.8 million in total revenue for the quarter, including $2.3 million in product sales and $0.5 million in licensing revenue. Pharmacy orders rose 102% quarter-over-quarter and prescribers exceeded 500 (55% growth QoQ). Q3 operating expenses were $7.5 million, operating loss was $5.3 million, and net loss improved to $1.3 million. Cash was $35.4 million at Sept 30, 2025, with an October capital raise adding $37.8 million net for ~$73.2 million pro forma cash and an estimated ~two-year runway at forecasted levels.
Alpha Cognition (Nasdaq: ACOG) will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025 at 4:30 p.m. ET after market close.
The company will publish a press release and supporting materials on its investor news page and host a live conference call and webcast following the release; a replay will be available via dial-in and webcast.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data on cholinesterase inhibitors and ZUNVEYL® (benzgalantamine) at two scientific meetings in late 2025. The company will present poster sessions at the ASCP Annual Meeting (Oct 23–25, 2025) and the NEI Annual Congress (Nov 6–9, 2025).
Accepted posters cover AChEI topics including persistence of therapy, switching methodologies, interactions with psychotropic medications, and literature reviews on effects on mortality and sleep in Alzheimer’s disease and related dementias.
The company says ZUNVEYL is an enteric-coated prodrug designed to combine cholinesterase inhibition with nicotinic receptor modulation to improve treatment continuity.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.
On October 24, 2025 the company will present three posters: Poster 12 — Acetylcholinesterase Inhibitors and Psychotropic Medication Use in ADRD; Poster 3 — Persistence of Therapy in ADRD; and Poster 4 — Evidence-Based Approaches to Switching AChEIs in Alzheimer’s Disease. Presentations include insights on cholinesterase inhibitors and ZUNVEYL (benzgalantamine) aimed at updating evidence-based guidance for clinicians treating older adults with neurodegenerative disease.
Alpha Cognition (Nasdaq: ACOG) has announced the pricing of its oversubscribed public offering of 5.6 million common shares at $6.25 per share, raising approximately $35 million in gross proceeds. The offering includes a 30-day over-allotment option for an additional 840,000 shares.
The company's total cash position is expected to reach $70 million post-closing. The proceeds will fund the commercial launch acceleration of ZUNVEYL® (Benzgalantamine), focusing on sales expansion, marketing investment, and enhancing payer coverage and reimbursement infrastructure in the Alzheimer's treatment market.
The offering, led by Titan Partners Group, is expected to close around October 2, 2025, with strong participation from both existing shareholders and a premier healthcare-dedicated investor.